{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:53:49Z","timestamp":1791327229733,"version":"4.3.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"iBio Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-59882-0","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:13:02Z","timestamp":1782850382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical development of an extended half-life anti-myostatin monoclonal antibody"],"prefix":"10.1038","volume":"16","author":[{"given":"Tom","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam","family":"Phuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Zour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"DiMartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Crutcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"59882_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh, D. P. et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public. Health. 9, 88. https:\/\/doi.org\/10.1186\/1471-2458-9-88 (2009).","journal-title":"BMC Public. Health"},{"key":"59882_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","volume":"6","author":"DH Bessesen","year":"2018","unstructured":"Bessesen, D. H. & Van Gaal, L. F. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 6, 237\u2013248. https:\/\/doi.org\/10.1016\/S2213-8587(17)30236-X (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"59882_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz, A. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Ann. Intern. Med. 178, 199\u2013217. https:\/\/doi.org\/10.7326\/ANNALS-24-01590 (2025).","journal-title":"Ann. Intern. Med."},{"key":"59882_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"Moiz, A. et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. Am. J. Med. 138, 934\u2013940. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021 (2025).","journal-title":"Am. J. Med."},{"key":"59882_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: A systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am. J. Clin. Nutr. 118, 614\u2013626. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.017 (2023).","journal-title":"Am. J. Clin. Nutr."},{"key":"59882_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006748","author":"P Medhati","year":"2025","unstructured":"Medhati, P. et al. GLP-1RA in the real world: 1-year compliance and outcomes of Semaglutide use in patients with or without previous history of bariatric surgery. Ann. Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000006748 (2025).","journal-title":"Ann. Surg."},{"key":"59882_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/oby.24331","volume":"33","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan, H. et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obes. (Silver Spring). 33, 1657\u20131667. https:\/\/doi.org\/10.1002\/oby.24331 (2025).","journal-title":"Obes. (Silver Spring)"},{"issue":"Suppl 2","key":"59882_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","volume":"27","author":"RW Thomsen","year":"2025","unstructured":"Thomsen, R. W., Mailhac, A., Lohde, J. B. & Pottegard, A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes. Metab. 27 (Suppl 2), 66\u201388. https:\/\/doi.org\/10.1111\/dom.16364 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"59882_CR9","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1056\/NEJMc2106918","volume":"385","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H., Calanna, S. & Kushner, R. F. Once-weekly Semaglutide in adults with overweight or obesity. Reply. N Engl. J. Med. 385, e4. https:\/\/doi.org\/10.1056\/NEJMc2106918 (2021).","journal-title":"N Engl. J. Med."},{"key":"59882_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553\u20131564. https:\/\/doi.org\/10.1111\/dom.14725 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"59882_CR11","doi-asserted-by":"publisher","first-page":"e12622","DOI":"10.1111\/cob.12622","volume":"14","author":"A Grannell","year":"2024","unstructured":"Grannell, A., Al-Najim, W. & le Roux, C. Long-term weight outcomes in patients treated with liraglutide 3.0\u00a0mg in real-world clinical practice. Clin. Obes. 14, e12622. https:\/\/doi.org\/10.1111\/cob.12622 (2024).","journal-title":"Clin. Obes."},{"key":"59882_CR12","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West, S. et al. Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ 392, e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304 (2026).","journal-title":"BMJ"},{"key":"59882_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14060344","author":"H Wang","year":"2024","unstructured":"Wang, H., He, W., Yang, G., Zhu, L. & Liu, X. The impact of weight cycling on health and obesity. Metabolites https:\/\/doi.org\/10.3390\/metabo14060344 (2024).","journal-title":"Metabolites"},{"key":"59882_CR14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-025-09963-8","volume":"26","author":"M Zamboni","year":"2025","unstructured":"Zamboni, M. et al. Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity. Rev. Endocr. Metab. Disord. 26, 767\u2013783. https:\/\/doi.org\/10.1007\/s11154-025-09963-8 (2025).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"59882_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083a0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83\u201390. https:\/\/doi.org\/10.1038\/387083a0 (1997).","journal-title":"Nature"},{"key":"59882_CR16","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/pnas.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee, S. J. & McPherron, A. C. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U S A. 98, 9306\u20139311. https:\/\/doi.org\/10.1073\/pnas.151270098 (2001).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"59882_CR17","doi-asserted-by":"publisher","unstructured":"Lee, S. J. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI148372 (2021).","DOI":"10.1172\/JCI148372"},{"key":"59882_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"M St Andre","year":"2017","unstructured":"St Andre, M. et al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet. Muscle. 7, 25. https:\/\/doi.org\/10.1186\/s13395-017-0141-y (2017).","journal-title":"Skelet. Muscle"},{"key":"59882_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","volume":"30","author":"KR Wagner","year":"2020","unstructured":"Wagner, K. R. et al. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul. Disord. 30, 492\u2013502. https:\/\/doi.org\/10.1016\/j.nmd.2020.05.002 (2020).","journal-title":"Neuromuscul. Disord"},{"key":"59882_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","volume":"5","author":"E Latres","year":"2015","unstructured":"Latres, E. et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet. Muscle. 5, 34. https:\/\/doi.org\/10.1186\/s13395-015-0060-8 (2015).","journal-title":"Skelet. Muscle"},{"key":"59882_CR21","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","volume":"14","author":"RC Smith","year":"2015","unstructured":"Smith, R. C. et al. Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol. Cancer Ther. 14, 1661\u20131670. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0681 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"59882_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jcsm.12331","volume":"9","author":"T Golan","year":"2018","unstructured":"Golan, T. et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: A randomized, phase 2 trial. J. Cachexia Sarcopenia Muscle. 9, 871\u2013879. https:\/\/doi.org\/10.1002\/jcsm.12331 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"59882_CR23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker, C. et al. Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 3, 948\u2013957. https:\/\/doi.org\/10.1016\/S2213-8587(15)00298-3 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"59882_CR24","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41598-021-81669-8","volume":"11","author":"H Muramatsu","year":"2021","unstructured":"Muramatsu, H. et al. Novel myostatin-specific antibody enhances muscle strength in muscle disease models. Sci. Rep. 11, 2160. https:\/\/doi.org\/10.1038\/s41598-021-81669-8 (2021).","journal-title":"Sci. Rep."},{"key":"59882_CR25","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","volume":"8","author":"M Pirruccello-Straub","year":"2018","unstructured":"Pirruccello-Straub, M. et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292. https:\/\/doi.org\/10.1038\/s41598-018-20524-9 (2018).","journal-title":"Sci. Rep."},{"key":"59882_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12915-017-0350-1","volume":"15","author":"RG Walker","year":"2017","unstructured":"Walker, R. G. et al. Structural basis for potency differences between GDF8 and GDF11. BMC Biol. 15, 19. https:\/\/doi.org\/10.1186\/s12915-017-0350-1 (2017).","journal-title":"BMC Biol."},{"key":"59882_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmet.2015.05.010","volume":"22","author":"MA Egerman","year":"2015","unstructured":"Egerman, M. A. et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell. Metab. 22, 164\u2013174. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.010 (2015).","journal-title":"Cell. Metab."},{"key":"59882_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.15252\/emmm.201607231","volume":"9","author":"DW Hammers","year":"2017","unstructured":"Hammers, D. W. et al. Supraphysiological levels of GDF11 induce striated muscle atrophy. EMBO Mol. Med. 9, 531\u2013544. https:\/\/doi.org\/10.15252\/emmm.201607231 (2017).","journal-title":"EMBO Mol. Med."},{"key":"59882_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00395-017-0639-9","volume":"112","author":"TA Zimmers","year":"2017","unstructured":"Zimmers, T. A. et al. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. Basic. Res. Cardiol. 112, 48. https:\/\/doi.org\/10.1007\/s00395-017-0639-9 (2017).","journal-title":"Basic. Res. Cardiol."},{"key":"59882_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff, E. et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol. Cell. Biol. 34, 606\u2013618. https:\/\/doi.org\/10.1128\/MCB.01307-13 (2014).","journal-title":"Mol. Cell. Biol."},{"key":"59882_CR31","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato, A. A. et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83, 2239\u20132246. https:\/\/doi.org\/10.1212\/WNL.0000000000001070 (2014).","journal-title":"Neurology"},{"key":"59882_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna, M. G. et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): A randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 18, 834\u2013844. https:\/\/doi.org\/10.1016\/S1474-4422(19)30200-5 (2019).","journal-title":"Lancet Neurol."},{"key":"59882_CR33","doi-asserted-by":"publisher","first-page":"e2020836","DOI":"10.1001\/jamanetworkopen.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks, D. et al. Bimagrumab vs. optimized standard of care for treatment of sarcopenia in community-dwelling older adults: A randomized clinical trial. JAMA Netw. Open. 3, e2020836. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.20836 (2020).","journal-title":"JAMA Netw. Open."},{"key":"59882_CR34","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(21)00084-2","volume":"2","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer, L. C. et al. Bimagrumab to improve recovery after hip fracture in older adults: A multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a\/b trial. Lancet Healthy Longev. 2, e263\u2013e274. https:\/\/doi.org\/10.1016\/S2666-7568(21)00084-2 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"59882_CR35","unstructured":"NCT05616013. (ed Inc Versanis Bio). (2022)."},{"key":"59882_CR36","doi-asserted-by":"publisher","first-page":"e209151","DOI":"10.1212\/WNL.0000000000209151","volume":"102","author":"TO Crawford","year":"2024","unstructured":"Crawford, T. O. et al. Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: The phase 2 TOPAZ study. Neurology 102, e209151. https:\/\/doi.org\/10.1212\/WNL.0000000000209151 (2024).","journal-title":"Neurology"},{"key":"59882_CR37","doi-asserted-by":"publisher","first-page":"1419791","DOI":"10.3389\/fneur.2024.1419791","volume":"15","author":"TO Crawford","year":"2024","unstructured":"Crawford, T. O. et al. Long-term efficacy, safety, and patient-reported outcomes of Apitegromab in patients with spinal muscular atrophy: Results from the 36-month TOPAZ study. Front. Neurol. 15, 1419791. https:\/\/doi.org\/10.3389\/fneur.2024.1419791 (2024).","journal-title":"Front. Neurol."},{"key":"59882_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(25)00225-X","volume":"24","author":"TO Crawford","year":"2025","unstructured":"Crawford, T. O. et al. Safety and efficacy of Apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 24, 727\u2013739. https:\/\/doi.org\/10.1016\/S1474-4422(25)00225-X (2025).","journal-title":"Lancet Neurol."},{"key":"59882_CR39","unstructured":"NCT06445075. (2024)."},{"key":"59882_CR40","unstructured":"NCT01963598. (ed Sanofi). (2013)."},{"key":"59882_CR41","unstructured":"NCT06299098. (2024)."},{"key":"59882_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159. https:\/\/doi.org\/10.1038\/nbt.1601 (2010).","journal-title":"Nat. Biotechnol."},{"key":"59882_CR43","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514\u201323524. https:\/\/doi.org\/10.1074\/jbc.M604292200 (2006).","journal-title":"J. Biol. Chem."},{"key":"59882_CR44","doi-asserted-by":"publisher","unstructured":"Datta-Mannan, A., Witcher, D. R., Lu, J. & Wroblewski, V. J. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4, 267\u2013273 (2012). https:\/\/doi.org\/10.4161\/mabs.4.2.19364","DOI":"10.4161\/mabs.4.2.19364"},{"key":"59882_CR45","doi-asserted-by":"publisher","first-page":"e22018","DOI":"10.1096\/fj.202101244R","volume":"35","author":"R Kumari","year":"2021","unstructured":"Kumari, R. et al. SMAD2 and SMAD3 differentially regulate adiposity and the growth of subcutaneous white adipose tissue. FASEB J. 35, e22018. https:\/\/doi.org\/10.1096\/fj.202101244R (2021).","journal-title":"FASEB J."},{"key":"59882_CR46","doi-asserted-by":"publisher","unstructured":"Aykul, S., Maust, J., Thamilselvan, V., Floer, M. & Martinez-Hackert, E. Smad2\/3 Activation Regulates Smad1\/5\/8 Signaling via a Negative Feedback Loop to Inhibit 3T3-L1 Adipogenesis. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22168472 (2021).","DOI":"10.3390\/ijms22168472"},{"key":"59882_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13287-020-1552-y","volume":"11","author":"SN Li","year":"2020","unstructured":"Li, S. N. & Wu, J. F. TGF-beta\/SMAD signaling regulation of mesenchymal stem cells in adipocyte commitment. Stem Cell. Res. Ther. 11, 41. https:\/\/doi.org\/10.1186\/s13287-020-1552-y (2020).","journal-title":"Stem Cell. Res. Ther."},{"key":"59882_CR48","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","volume":"25","author":"A Bikou","year":"2024","unstructured":"Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K. & Kontogiorgis, C. A systematic review of the effect of semaglutide on lean mass: Insights from clinical trials. Expert Opin. Pharmacother. 25, 611\u2013619. https:\/\/doi.org\/10.1080\/14656566.2024.2343092 (2024).","journal-title":"Expert Opin. Pharmacother"},{"key":"59882_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.70141","volume":"28","author":"M Alissou","year":"2026","unstructured":"Alissou, M. et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes. Metab. 28, 112\u2013121. https:\/\/doi.org\/10.1111\/dom.70141 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"59882_CR50","doi-asserted-by":"publisher","first-page":"e12631","DOI":"10.1111\/cpr.12631","volume":"52","author":"H Luo","year":"2019","unstructured":"Luo, H. et al. Growth differentiation factor 11 inhibits adipogenic differentiation by activating TGF-beta\/Smad signalling pathway. Cell. Prolif. 52, e12631. https:\/\/doi.org\/10.1111\/cpr.12631 (2019).","journal-title":"Cell. Prolif."},{"key":"59882_CR51","doi-asserted-by":"publisher","first-page":"e13310","DOI":"10.1111\/cpr.13310","volume":"55","author":"J Frohlich","year":"2022","unstructured":"Frohlich, J. et al. GDF11 inhibits adipogenesis and improves mature adipocytes metabolic function via WNT\/beta-catenin and ALK5\/SMAD2\/3 pathways. Cell. Prolif. 55, e13310. https:\/\/doi.org\/10.1111\/cpr.13310 (2022).","journal-title":"Cell. Prolif."},{"key":"59882_CR52","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1038\/s41598-020-61443-y","volume":"10","author":"RG Walker","year":"2020","unstructured":"Walker, R. G. et al. Exogenous GDF11, but not GDF8, reduces body weight and improves glucose homeostasis in mice. Sci. Rep. 10, 4561. https:\/\/doi.org\/10.1038\/s41598-020-61443-y (2020).","journal-title":"Sci. Rep."},{"key":"59882_CR53","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield, S. B. et al. Effect of Bimagrumab vs. Placebo on body fat mass among adults with type 2 diabetes and obesity: A phase 2 randomized clinical trial. JAMA Netw. Open. 4, e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457 (2021).","journal-title":"JAMA Netw. Open."},{"key":"59882_CR54","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.molmet.2024.101880","volume":"80","author":"E Nunn","year":"2024","unstructured":"Nunn, E. et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol. Metab. 80, 101880. https:\/\/doi.org\/10.1016\/j.molmet.2024.101880 (2024).","journal-title":"Mol. Metab."},{"key":"59882_CR55","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","volume":"16","author":"JW Mastaitis","year":"2025","unstructured":"Mastaitis, J. W. et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nat. Commun. 16, 4377. https:\/\/doi.org\/10.1038\/s41467-025-59485-9 (2025).","journal-title":"Nat. Commun."},{"key":"59882_CR56","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1124\/dmd.112.045864","volume":"40","author":"A Datta-Mannan","year":"2012","unstructured":"Datta-Mannan, A. et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab. Dispos. 40, 1545\u20131555. https:\/\/doi.org\/10.1124\/dmd.112.045864 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"59882_CR57","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/19420862.2016.1215786","volume":"8","author":"JR Apgar","year":"2016","unstructured":"Apgar, J. R. et al. Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody. MAbs 8, 1302\u20131318. https:\/\/doi.org\/10.1080\/19420862.2016.1215786 (2016).","journal-title":"MAbs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59882-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59882-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:47:45Z","timestamp":1791326865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59882-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59882"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59882-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B., A.T., C.M., H.Z., M.D., A.H., T.P., C.Z., T.H., and C.S. are employees of iBio Inc. at the time of work completion. J.D. and P.C. are employees of AstralBio Inc. at the time of work completion.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31168"}}